Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

Nicolas Gauthier, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Nathalie Parquet, MD, Jean-Marc Zini, Delphine Rea, MDPhD, Emmanuel Raffoux, MD, Bruno Cassinat, PharmD, PhD, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-141260

Published: 2020

Journal Articles

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Clemence Marcault, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, MD, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD PhD, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141296

Published: 2020

Journal Articles

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Clemence Marcault, MD, Lin-Pierre Zhao, MD, Rafael Daltro De Oliveira, MD, Juliette Soret, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Blandine Roux, MSc, Nathalie Parquet, MD, Christine Dosquet, MD, Delphine Rea, MDPhD, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, MD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, Lina Benajiba, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-136177

Published: 2020

Journal Articles

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

Rafael Daltro De Oliveira, MD, Juliette Soret-Dulphy, MD, Lin-Pierre Zhao, MD, Clemence Marcault, MD, Nicolas Gauthier, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Nathalie Parquet, MD, Emmanuel Raffoux, MD, William Vainchenker, Christine Chomienne, MD PhD, Bruno Cassinat, PharmD, PhD, Lina Benajiba, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141223

Published: 2020

Journal Articles

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Blood (2019) 134 (Supplement_1): 3876.

https://doi.org/10.1182/blood-2019-131123

Published: 2019

Journal Articles

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Juliette Soret, MD, Bruno Cassinat, PharmD, PhD, Sylvie Chevret, MD PhD, Christine Dosquet, MD PhD, Stephane Giraudier, MD PhD, Emmanuelle Verger, PhD, Nabih Maslah, PhD, Nathalie Parquet, MD, Christine Chomienne, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 3106.

https://doi.org/10.1182/blood.V128.22.3106.3106

Published: 2016

Journal Articles

Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain

Annalisa Andreoli, MD, Emmanuelle Verger, PhD, Marie Robin, MD, PhD, Emmanuel Raffoux, Jean-Marc Zini, MD, PhD, Philippe Rousselot, MD, PhD, Gérard Socié, MD, PhD, Delphine Rea, MD, PhD, Nathalie Parquet, MD, Stephane Giraudier, MD, PhD, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD, PhD, Jean-Jacques Kiladjian, MD, PhD

Blood (2013) 122 (21): 1591.

https://doi.org/10.1182/blood.V122.21.1591.1591

Published: 2013

Journal Articles

Mutations in the Exon 12 of the JAK2 Gene Appeared To Be a Rare Event Essentially Clustered in V617F JAK2 Negative PV Patients.

Eirini Kouroupi, MD, Nathalie Parquet, MD, Christine Zoi, MD, Jean-Jacques Kiladjian, MD, Vassiliki Grigoraki, MD, Katerina Zoi, PhD, Linda Scott, PhD, Christine Dosquet, MD, Pierre Fenaux, MD, PhD, Dimitris Loukopoulos, MD, PhD, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD

Blood (2007) 110 (11): 2534.

https://doi.org/10.1182/blood.V110.11.2534.2534

Published: 2007

Journal Articles

The V617F JAK2 Mutation Is Very Uncommon in Idiopathic Erythrocytosis.

Bruno Cassinat, PharmD, Nathalie Parquet, MD, Jean-Jacques Kiladjian, MD, Gerald Massonnet, Marie-Laurence Menot, Christine Chomienne, MD-PHD

Blood (2006) 108 (11): 1295.

https://doi.org/10.1182/blood.V108.11.1295.1295

Published: 2006

Journal Articles

Can High Dose Therapy Change the Course of Low Grade Lymphoma? A Study Considering Patients as Their Own Control.

Stephane Vignot, MD, Nicolas Mounier, MD, Guillaume Sergent, MD, Pauline Brice, MD, Jean-Pierre Marolleau, MD, Nathalie Parquet, MD, Josette Briere, MD, Eric DeKerviller, MD, Isabelle Madeleine, PharmD, Christian Gisselbrecht, MD

Blood (2004) 104 (11): 1882.

https://doi.org/10.1182/blood.V104.11.1882.1882

Published: 2004

NARROW

Ruxolitinib Treatment Is Associated with Increased Incidence of Infections and Higher Risk of HSV/Vzv Recurrence in Patients with Myeloproliferative Neoplasm (MPN) Related Myelofibrosis (MF)

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain

Mutations in the Exon 12 of the JAK2 Gene Appeared To Be a Rare Event Essentially Clustered in V617F JAK2 Negative PV Patients.

The V617F JAK2 Mutation Is Very Uncommon in Idiopathic Erythrocytosis.

Can High Dose Therapy Change the Course of Low Grade Lymphoma? A Study Considering Patients as Their Own Control.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only